BETHESDA, MD – August 1, 2019 – Precision for Medicine, part of Precision Medicine Group, announced it has acquired leading biospecimen providers ProMedDx and GLAS, significantly expanding its capabilities and expertise in the biospecimen solutions space. With the acquisitions, Precision now offers an unmatched level of scientific understanding, high-quality specimen solutions, and global scale.The addition of ProMedDx and GLAS establishes an unrivalled biospecimen solutions platform within Precision, which operates one of the largest biorepositories in the world. ProMedDx is known throughout…

Stevenage Bioscience Catalyst (SBC), a leading location for development and commercialisation of cutting-edge therapeutics, is pleased to announce that James Keeling has been appointed as Chief Financial Officer (CFO). James joins from JGK Financial Management, a company set up to support SMEs in their growth phase providing expertise in business & financial planning, funding, sustainable investments and exit strategies. This has included working with business based in Loughborough University Science, Enterprise Park and as Interim CFO for Stevenage Bioscience Catalyst. Prior to founding…

             Cambridge, UK: 31st July 2019   ONE NUCLEUS STRENGTHENS BOARD WITH APPOINTMENT OF NEW DIRECTOR Life Sciences industry company operations and communications expert joins the region’s Life Science & Healthcare membership organisation   One Nucleus, the Cambridge based not-for-profit membership organisation for the East of England and London life sciences cluster, is delighted to announce the appointment of Rowena Gardner as a Non-Executive Director. Rowena is currently VP Operations and Company Secretary for Microbiotica.Rowena’s…

Westbury, NY – July 23, 2019 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today outlined several scientific contributions that it will be making at the 12th International ISSX Meeting. This conference will be held from July 28-31 at the Oregon Convention Center in Portland, OR. “We are excited to have this opportunity to showcase some of the research advances being made using our hepatic products and research services. They span research areas as diverse as investigating the impact of HIV integrase inhibitor drugs on folate transporters and…

The AMR Centre Ltd has today announced a landmark agreement with the Japanese pharma company Shionogi to take forward its anti-virulence program, COT-143. The therapy is designed to help the body tackle Pseudomonas aeruginosa infections, a hard to treat drug-resistant pathogen recognised by the WHO as a critical threat to human health. COT-143 is a novel humanized monoclonal antibody. It does not kill bacteria directly but targets an element that prevents the immune system from acting against the infection. COT-143 has already produced encouraging results in pre-clinical studies and…

AMSBIO has introduced a new range of homogeneous proximity assays, critical enzymes and small molecule inhibitors to assess the chemical adaptor function of Proteolysis Targeting Chimeras (PROTACs).Targeted protein degradation using PROTACs is a new and promising therapeutic method in drug discovery. PROTACs have the ability to regulate protein degradation through targeted control of ubiquitin E3 ligases. This novel technology allows for the degradation of disease-related proteins and offers many advantages over traditional protein inhibition.The PROTAC method offers many advantages compared…

Closed Loop Medicine (CLM) announces £1.3m grant funding from Innovate UK, Longwall Capital and IQ Capital as part of today’s IUK £16m funding announcement. CLM is an early stage UK therapeutics company focused on care pathways, outcomes and the provision of dynamic personalised therapy regimens underpinned by digital health solutions.  The company combines proven drugs with digital engagement, medical devices and behavioural therapeutic interventions enabling data capture of a whole care pathway. This data is then used to tailor and create …

Research Triangle Park, NC, USA and Cambridge, UK, and Lyon, France,  July 18, 2019 -- Inivata, a leader in liquid biopsy, and the Centre Léon Bérard cancer center in Lyon, France, today announce the start of a randomized phase III clinical trial to evaluate time to appropriate treatment in patients with suspected metastatic lung cancer, using Inivata’s InVisionFirst®-Lung liquid biopsy test compared to standard of care tissue biopsy. This is the first interventional study for Inivata’s InVisionFirst-Lung liquid biopsy test. The ‘LIquid Biopsy for the Early detection of…

Cambridge, UK, 17 July 2019: Mogrify Ltd (Mogrify), a company aiming to transform the future development of cell therapies, today announced it will host a careers day at the Bio-Innovation Centre, 25 Cambridge Science Park on Friday, 16th August 2019 from 4–6pm. The event will showcase careers in the biotech industry, specifically in cell therapy and regenerative medicine, and offer attendees the opportunity to visit the Company’s research laboratories, and meet with the founders and current employees. Mogrify has developed a proprietary direct cellular conversion technology, which makes it…

Alloy Therapeutics UK Ltd are a start-up company from the USA and required lab and office space for 15 scientist with two Cat II cell biology labs, a Cat II molecular biology lab for 10, a meeting room and write up space.  They wanted to be on Granta Park so the only space was at the McClintock Building which was designed as an office building. The suite of 1800 sq. ft. had been split into two units, comprising of a small laboratory in 600 sq. ft. and an office in the other 1200 sq. ft. Alloy required the configuration to be the other way around with the laboratory being in the…